Ombitasvir/Paritaprevir/Ritonavir
- Generic Name
- Ombitasvir/Paritaprevir/Ritonavir
- Indication
用于治疗成人基因1型慢性丙型肝炎，包括无肝硬化或伴代偿期肝硬化的患者。该治疗方案是全口服的、无干扰素、可联合或不联合利巴韦林。
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
Phase 3
Completed
- Conditions
- Hepatitis C VirusChronic Hepatitis CCirrhosis
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 99
- Registration Number
- NCT02442284
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 29
- Registration Number
- NCT02356562
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Chronic Hepatitis C Virus Infection
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT02292719
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
Phase 3
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 184
- Registration Number
- NCT02265237
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
Phase 3
Completed
- Conditions
- Chronic Hepatitis C InfectionCompensated Cirrhosis
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT02219503
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
Phase 3
Completed
- Conditions
- Chronic Hepatitis CDecompensated CirrhosisHepatitis C Virus
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02219477
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1596
- Registration Number
- NCT02219490
- Locations
- 🇳🇴
Akershus Universitetssykehus_MAIN /ID# 132212, Lorenskog, Akershus, Norway
🇩🇰Odense University Hospital /ID# 131029, Odense C, Syddanmark, Denmark
🇩🇰Aarhus Univ Hospital, Skejby /ID# 131030, Aarhus, Denmark
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02216422
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Hepatitis C VirusCompensated CirrhosisEnd-stage Renal DiseaseChronic Hepatitis CSevere Renal Impairment
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 68
- Registration Number
- NCT02207088
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- Interventions
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 615
- Registration Number
- NCT02167945
- Locations
- 🇺🇸
St. Josephs Hospital and Med Center /ID# 127800, Phoenix, Arizona, United States
🇺🇸Univ of Colorado Cancer Center /ID# 126568, Aurora, Colorado, United States
🇺🇸Encore Borland-Groover Clinical Research /Id# 127781, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath